vimarsana.com

Page 279 - தொழில் முனைவோர் மகேந்திரா நாத் பாண்டே News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans

Published: Mar 29, 2021     CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that each of its Executive Vice President and Chief Financial Officer, Steve Forte and its Executive Vice President and Chief Medical Officer, Maria Koehler (collectively, the “Executives”), have established Automatic Securities Disposition Plans (“ASDPs”) in accordance with applicable United States and Canadian securities legislation, including U.S. Securities and Exchange Commission (“SEC”) rule 10b5-1 and the recommended practices set forth in the recently issued Canadian Securities Administrators’ Staff Notice 55-317 (“Staff Notice 55-317”) and the Company’s internal policies.

Chris Adams memory lives on to support UniSA brain cancer research

UniSA PhD student Kaitlin Scheer flanked by Chris Adam’s parents, Marty and Cherrie. The family of a young man who lost his battle with brain cancer is financially supporting UniSA PhD candidate Kaitlin Scheer to help find a cure for the deadly disease. Kaitlin has been awarded a $5000 Chris Adams Research Grant to develop a model which better predicts poor glioblastoma responders, allowing them to pursue different treatment options. Chris Adams lost his battle in November 2015 after being diagnosed with a rare grade-three anaplastic astrocytoma brain tumour. His family is honouring his memory by supporting the Neurosurgical Research Foundation which funds vital research into brain cancer.

Rising Glaucoma Prevalence to Spur Advanced Glaucoma Diagnostics Deployment

Published: Apr 01, 2021 Software integration is touted as the most important therapeutic advancements, likely to yield promising results Fact.MR, Rockville MD: The glaucoma diagnostics market is anticipated to post substantial gains through 2021 and beyond, as ophthalmic clinics resume elective surgeries in the post-pandemic scenario. Long-term prospects are expected to remain underpinned by immense promises exhibited by virtue of technological integration to fast-track surgical procedures and reduction of patient trauma. According to a study published in the National Center for Biotechnology Information, global prevalence of glaucoma for the population aged 40-80 years is over 3%, with primary open angle glaucoma prevalence being the highest in Africa (4.2%), while incidence of primary angle closure glaucoma is the highest in Asia, at 1.1%. It was further established that the total number of glaucoma patients would rise to 76 million by 2020, and further to 111.8 million by

Study underscores need for ag research funding

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.